Published in

Oxford University Press, Clinical Infectious Diseases, 2(75), p. 334-337, 2021

DOI: 10.1093/cid/ciab1026

Links

Tools

Export citation

Search in Google Scholar

Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors—United States, July 2016–June 2019

Journal article published in 2021 by Jeremy A. W. Gold ORCID, Seda S. Tolu, Tom Chiller, Kaitlin Benedict, Brendan R. Jackson
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).